Detalhe da pesquisa
1.
Adoptive cell therapies in thoracic malignancies.
Cancer Immunol Immunother
; 71(9): 2077-2098, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35129636
2.
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.
J Immunother Cancer
; 12(4)2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631710
3.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer
; 201: 113589, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38382153
4.
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC.
Sci Adv
; 9(45): eadh0708, 2023 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939189
5.
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Front Immunol
; 14: 1270081, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37920468
6.
The use of immunotherapy in older patients with advanced non-small cell lung cancer.
Cancer Treat Rev
; 106: 102394, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35472632
7.
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Lung Cancer
; 166: 255-264, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953624
8.
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131864
9.
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.
Expert Rev Anticancer Ther
; 22(9): 915-926, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815381
10.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
J Immunother Cancer
; 10(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35640928
11.
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
Transl Lung Cancer Res
; 10(6): 2937-2954, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34295689
12.
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Clin Cancer Res
; 27(2): 492-503, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887723
13.
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
Eur J Cancer
; 151: 211-220, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34022698
14.
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
Cancers (Basel)
; 12(12)2020 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33287347
15.
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.
Nat Commun
; 11(1): 2168, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32358520